REGEN
ToolsNotesBlogFAQ
← The board27/100 reports · directional
Community read · grade S · Regulatory approval

Tirzepatide

A dual GIP/GLP-1 receptor agonist offering strong appetite suppression and glucose…

Built from 27 anonymous reports · leaning, but thin

The read

What people observed

Every report answers on a 1–5 scale. This is the whole distribution, never an average pretending to be one number, though the average is beside it.

n=27
1 · no effect
6
2 · barely
5
3 · modest
3
4 · clearly worked
9
5 · textbook
4
3.0/5
Average reported outcome
78%
Would run it again
27
Reports filed · directional

What it did, and what else showed up

Counts across this compound's reports, never an average. One report can select several answers.

Reported positive outcomes

joint / tendon relief
8
injury healing
6
skin / hair
5
mood / focus
5
fat loss
4
better sleep
3
cognition
3
cardiovascular / circulation
3
faster recovery
2
libido
2
strength / pump
2
better bloodwork
2
more energy
1

Reported side effects

Kept separate from positive outcomes on purpose.

headache
6
sleep disruption
5
none / clean
4
fatigue
4
GI / nausea
4
mood / anxiety
4
injection-site irritation
3
appetite change
3
heart rate
2

How it was run

What people brought it in for, and how long they stayed on it. Intent, not a result or a treatment claim.

What people were researching

skin / hair
3
body composition
2
cardiovascular / blood pressure
2
longevity / healthspan
2
appetite / weight
1
energy / endurance
1
recovery / injury
1
sleep
1
mood / anxiety
1
libido / sexual function
1

How long they ran it

1 wk
4
2 wk
5
4 wk
1
6 wk
4
8 wk
4
12 wk
6
16 wk+
3
Safety

Anecdote, never medical advice.

These are anonymous personal reports on an experimental research compound, not clinical evidence, and they never set the grade. Talk to a licensed clinician before you start, stop, or change a dose.

Put the whole protocol
in one place.